Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors (LIBRETTO-121)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03899792
Recruitment Status : Recruiting
First Posted : April 2, 2019
Last Update Posted : April 2, 2019
Sponsor:
Information provided by (Responsible Party):
Loxo Oncology, Inc.

Brief Summary:
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric patients with an activating RET alteration and an advanced solid or primary CNS tumor.

Condition or disease Intervention/treatment Phase
Medullary Thyroid Cancer Infantile Myofibromatosis Infantile Fibrosarcoma Papillary Thyroid Cancer Soft Tissue Sarcoma Drug: LOXO-292 Phase 1 Phase 2

Detailed Description:
This study includes 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). In phase 1, patients will be enrolled using a rolling 6 dose escalation scheme. The starting dose of LOXO-292 is equivalent to the adult recommended phase 2 dose of 160mg BID. Once the MTD and/or RP2D is identified, patients will be enrolled to one of four phase 2 dose expansion cohorts depending on tumor histology and tumor genotype. Cycle length will be 28 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
Estimated Study Start Date : April 2019
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : October 2022


Arm Intervention/treatment
Experimental: LOXO-292
Phase 1- Dose Escalation and determination of MTD; multiple dose levels of LOXO-292 to be evaluated; Phase 2 - The maximum tolerated dose (MTD)/recommended dose from Phase 1
Drug: LOXO-292
Oral LOXO-292




Primary Outcome Measures :
  1. To determine the safety of oral LOXO-292 in pediatric patients with advanced solid tumors: Dose limiting toxicities (DLTs) [ Time Frame: During the first 28-day cycle of LOXO-292 treatment ]
    For Phase 1

  2. To determine the safety of oral LOXO-292 in pediatric patients with primary central nervous system (CNS) tumors: Dose limiting toxicities (DLTs) [ Time Frame: During the first 28-day cycle of LOXO-292 treatment ]
    For Phase 1

  3. ORR based on RECIST 1.1 per IRC [ Time Frame: Baseline to Progressive Disease or Death due to any cause (Estimated up to 12 months) ]
    For Phase 2

  4. ORR based on RANO per IRC [ Time Frame: Baseline to Progressive Disease or Death due to any cause (Estimated up to 12 months) ]
    For Phase 2


Secondary Outcome Measures :
  1. Plasma concentrations of LOXO-292 [ Time Frame: Days 1 & 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-patient Dose Escalation (each cycle is 28 days) ]
    Phase 1

  2. AUC0-24 of LOXO-292 [ Time Frame: Days 1 & 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-patient Dose Escalation (each cycle is 28 days) ]
    Phase 1 & Phase 2

  3. Cmax of LOXO-292 [ Time Frame: Days 1 & 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-patient Dose Escalation (each cycle is 28 days) ]
    Phase 1 & Phase 2

  4. Tmax of LOXO-292 [ Time Frame: Days 1 & 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-patient Dose Escalation (each cycle is 28 days) ]
    Phase 1 & Phase 2

  5. Recommended LOXO-292 Dose for Phase 2 (Maximum Tolerated Dose [MTD]) [ Time Frame: Cycle 1 (28 days) ]
    For Phase 1

  6. To assess the preliminary anti-tumor activity of LOXO-292 in pediatric patients with tumors harboring an activating RET alteration as determined by ORR based on RECIST v1.1 [ Time Frame: Baseline to Progressive Disease or Death due to any cause (Estimated up to 12 months) ]
    For Phase 1

  7. Changes from baseline in pain measures as measured by Wong Baker Faces scales. Wong-Baker Faces Pain Scale includes pictures of facial expressions with correlating scores of 0 being 'no hurt' and 10 being 'hurts worst'. [ Time Frame: Up to 24 months ]
    For Phase 1

  8. Changes from baseline in health related quality of life measures as measured by Pediatric Quality of Life Inventory Core. PedsQoL includes a list of problems with scores of 0 being 'never a problem' and 4 being 'almost always a problem'. [ Time Frame: Up to 24 months ]
    For Phase 1

  9. Objective Response Rate as assessed by RECIST v1.1, as assessed by investigator [ Time Frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed. ]
    For Phase 2

  10. Objective Response Rate as assessed by RANO, as assessed by investigator [ Time Frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed. ]
    For Phase 2

  11. Duration of response (DOR) as assessed by the Investigator [ Time Frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed. ]
    For Phase 2

  12. Duration of response (DOR) as assessed by the IRC [ Time Frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed. ]
    For Phase 2

  13. Progression free survival (PFS) as assessed by the Investigator [ Time Frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed. ]
    For Phase 2

  14. Progression free survival (PFS) as assessed by the IRC [ Time Frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed. ]
    For Phase 2

  15. Overall survival (OS) [ Time Frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed. ]
    For Phase 2

  16. Clinical Benefit Rate (by Investigator) [ Time Frame: Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in patients who have not progressed. ]
    For Phase 2

  17. Clinical Benefit Rate (by IRC) [ Time Frame: Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in patients who have not progressed. ]
    For Phase 2

  18. Frequency of AEs [ Time Frame: From the time of informed consent, for approximately 24 months (or earlier if the patient discontinues from the study), and through Safety Follow-up (28 days after the last dose) ]
    For Phase 2

  19. To evaluate the concordance of prior molecular profiling that detected a RET alteration within the subject's tumor with diagnostic tests being evaluated by the Sponsor [ Time Frame: 6 months ]
    For Phase 2

  20. Phase 2: Post-operative stage on patients treated with LOXO-292. [ Time Frame: Up to 3 years ]
    Tumor stage is described according to the TNM Classification of malignant tumors of the Union for International Cancer Control (UICC).

  21. Phase 2: Surgical margin status in patients treated with LOXO-292. [ Time Frame: Up to 3 years ]
    Tumor margins after surgery are classified into four groups using the International Cancer Control (UICC)-R classification and the Intergroup Rhabdomyosarcoma Staging (IRS) systems: 1) Complete tumor resection with histologically free margins, 2) Macroscopic resection but invaded margins on histology, 3)Macroscopic residual tumor and 4) Distant metastatic tumor.

  22. Descriptive analysis of pretreatment surgical plan [ Time Frame: Up to 3 years ]
    For Phase 2

  23. TDescriptive analysis of post-treatment plans [ Time Frame: Up to 3 years ]
    For Phase 2



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Advanced or metastatic solid or primary CNS tumor which has failed standard of care therapies
  • Evidence of an activating RET gene alteration in the tumor and/ or blood
  • Measurable or evaluable disease
  • Karnofsky (patients 16 years and older) or Lansky (patients younger than 16) performance score of at least 50.
  • Patient with primary CNS tumors or cerebral metastases must be neurologically stable for 7 days prior and must not have required increasing doses of steroids within the last 7 days.
  • Adequate hematologic, hepatic and renal function.
  • Ability to receive study drug therapy orally or via gastric access
  • Willingness of men and women of reproductive potential to observe conventional and effective birth control

Exclusion Criteria:

  • Major surgery within 14 days prior to planned start of LOXO-292.
  • Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of LOXO-292.
  • Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.
  • Clinically significant active malabsorption syndrome.
  • Pregnancy or lactation
  • Uncontrolled symptomatic hyperthyroidism or hypothyroidism (i.e. the patient required a modification to current thyroid medication in the 7 days prior to first dose of study treatment)."
  • Uncontrolled symptomatic hypercalcemia or hypocalcemia.
  • Current treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers.
  • Known hypersensitivity to any of the components of the investigational agent, LOXO-292 or Ora-Sweet® SF and OraPlus®, for patients who will receive LOXO-292 suspension.
  • Current treatment with proton pump inhibitors.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03899792


Contacts
Layout table for location contacts
Contact: Patient Advocacy 855-RET-4-292 (855-738-4292) clinicaltrials@loxooncology.com

Locations
Layout table for location information
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
United States, Texas
University of Texas, Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75235
United States, Washington
Seattle Children's Recruiting
Seattle, Washington, United States, 98105
Sponsors and Collaborators
Loxo Oncology, Inc.
Investigators
Layout table for investigator information
Study Director: Michael Cox, PharmD,MHSc, BCOP Loxo Oncology

Layout table for additonal information
Responsible Party: Loxo Oncology, Inc.
ClinicalTrials.gov Identifier: NCT03899792     History of Changes
Other Study ID Numbers: LOXO-RET-18036
2019‐000212‐28 ( EudraCT Number )
First Posted: April 2, 2019    Key Record Dates
Last Update Posted: April 2, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Loxo Oncology, Inc.:
Neoplasms by Site
Neoplasms
Non-Small Cell Lung Cancer
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Cancer of Lung
Cancer of the Lung
Lung Cancer
Neoplasms, Lung
Neoplasms, Pulmonary
Pulmonary Cancer
Pulmonary Neoplasms
Respiratory Tract Neoplasms
Lung Diseases
Bronchial Neoplasms
Medullary Thyroid Cancer
Papillary Thyroid Cancer
Thyroid Neoplasms
Cancer of the Thyroid
Cancer of Thyroid
Neoplasms, Thyroid
Thyroid Cancer
Endocrine Gland Neoplasms
Head and Neck Neoplasms
Thoracic Neoplasms
CNS tumor
Primary CNS tumor
Colonic Neoplasms
Cancer of Colon
Cancer of the Colon

Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Nervous System Neoplasms
Central Nervous System Neoplasms
Thyroid Cancer, Papillary
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Sarcoma
Thyroid Diseases
Carcinoma, Neuroendocrine
Fibrosarcoma
Myofibromatosis
Endocrine System Diseases
Nervous System Diseases
Adenocarcinoma, Papillary
Adenocarcinoma
Carcinoma